Accueil   Diary - News   All news Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

 

 

  • Novasep continues to consolidate its position as a leading CDMO for the production of
  • innovative and targeted molecules to treat cancer by investing in additional capacity
  • Responds to increasing customer demand for manufacturing services for Antibody Drug Conjugates (ADCs)
  • More than 30 full-time jobs to be created

 

 

Lyon, France – May 12, 2021 - Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce today a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities on its Le Mans (72 – France) site. This new step underlines customers' confidence in Novasep’s expertise in HPAPIs & ADCs and reinforces Novasep’s position as a leading CDMO for the production of innovative and targeted molecules to treat cancer.

 

Read the press release